{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:24:24Z","timestamp":1790270664102,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor approved for treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations, has significant clinical benefits. However, evidence suggests an increased risk of venous thromboembolism, including pulmonary embolism (PE), particularly in patients with PC. However, no case reports of olaparib-associated PE in mCRPC have been published. Here, we report the case of a 70-year-old man with mCRPC harboring a BRCA2 mutation, who developed PE during olaparib therapy. Diagnostic evaluations included contrast-enhanced computed tomography and serum D-dimer level measurement. Clinical decision tools, such as the Wells score and the Khorana score, were used to support the diagnosis and risk assessment. The patient developed acute dyspnea and chest pain 7 months after olaparib initiation. Imaging confirmed multiple pulmonary emboli; laboratory testing revealed markedly elevated D-dimer levels. Anticoagulation therapy with apixaban led to rapid clinical and radiological improvement. However, mCRPC eventually progressed after olaparib discontinuation, and the patient died 15 months after olaparib initiation. This is the first reported case of olaparib-associated PE in mCRPC. It underscores the importance of vigilance for thromboembolic complications during PARP inhibitor therapy. The integration of clinical scoring systems and biomarkers may facilitate timely PE diagnosis and management, potentially improving patient outcomes.<\/jats:p>","DOI":"10.3390\/curroncol32090523","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T08:11:01Z","timestamp":1758269461000},"page":"523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pulmonary Embolism Associated with Olaparib in BRCA2-Mutated Prostate Cancer: A Case Report"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-2104","authenticated-orcid":false,"given":"Shuhei","family":"Ishii","sequence":"first","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"},{"name":"Department of Urology, Iwate Prefectural Kamaishi Hospital, 10-483-6 Kasshi, Kamaishi 026-8550, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4620-2831","authenticated-orcid":false,"given":"Shigekatsu","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Prefectural Kamaishi Hospital, 10-483-6 Kasshi, Kamaishi 026-8550, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Prefectural Kamaishi Hospital, 10-483-6 Kasshi, Kamaishi 026-8550, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Ikarashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renpei","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Kanehira","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sugimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2720-9640","authenticated-orcid":false,"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[{"name":"Department of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"Mateo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Maekawa, S., Takata, R., and Obara, W. (2024). Molecular mechanisms of prostate cancer development in the precision medicine era: A comprehensive review. Cancers, 16.","DOI":"10.3390\/cancers16030523"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","article-title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study","volume":"170","author":"Roubaud","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The Phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1253\/circj.CJ-20-1247","article-title":"Mortality, recurrent thromboembolism and major bleeding in cancer-associated and non-cancer pulmonary embolism patients treated with direct oral anticoagulants","volume":"88","author":"Nakano","year":"2024","journal-title":"Circ. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.thromres.2021.09.012","article-title":"One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry","volume":"213","author":"Ohashi","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40119-022-00285-3","article-title":"Epidemiological study regarding the incidence of venous thromboembolism in patients after cancer remission","volume":"11","author":"Imura","year":"2022","journal-title":"Cardiol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pastori, D., Cormaci, V.M., Marucci, S., Franchino, G., Del Sole, F., Capozza, A., Fallarino, A., Corso, C., Valeriani, E., and Menichelli, D. (2023). A comprehensive review of risk factors for venous thromboembolism: From epidemiology to pathophysiology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043169"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","article-title":"Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe Sweden","volume":"11","author":"Adolfsson","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41391-018-0059-4","article-title":"Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: A systematic review and meta-analysis","volume":"21","author":"Guo","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/cncr.26623","article-title":"Androgen deprivation and thromboembolic events in men with prostate cancer","volume":"118","author":"Ehdaie","year":"2012","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.eururo.2015.06.022","article-title":"Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism","volume":"70","author":"Yin","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","unstructured":"Are You a Medical Practitioner?. Available online: https:\/\/med.astrazeneca.co.jp\/safety\/LYN.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.21037\/cdt.2017.12.01","article-title":"Imaging of acute pulmonary embolism: An update","volume":"8","author":"Moore","year":"2018","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ajem.2006.09.004","article-title":"The VIDAS D-dimer test for venous thromboembolism: A prospective surveillance study shows maintenance of sensitivity and specificity when used in normal clinical practice","volume":"25","author":"Mountain","year":"2007","journal-title":"Am. J. Emerg. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e7062","DOI":"10.1097\/MD.0000000000007062","article-title":"Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis","volume":"96","author":"Wu","year":"2017","journal-title":"Medicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.thromres.2020.09.031","article-title":"Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis","volume":"196","author":"Yang","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_26","first-page":"33","article-title":"Diagnosis of Pulmonary Embolism in the emergency department","volume":"61","author":"Adam","year":"2022","journal-title":"Acta Clin. Croat."},{"key":"ref_27","first-page":"e15064","article-title":"D-dimer: A potential solution to problems of cancer screening, surveillance, and prognosis assessment","volume":"13","author":"Siddiqui","year":"2021","journal-title":"Cureus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bharadwaj, A.G., Holloway, R.W., Miller, V.A., and Waisman, D.M. (2021). Plasmin and plasminogen system in the tumor microenvironment: Implications for cancer diagnosis, prognosis, and therapy. Cancers, 13.","DOI":"10.3390\/cancers13081838"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/oncolo\/oyad116","article-title":"Treatment of cancer-associated thrombosis: Recent advances, unmet needs, and future direction","volume":"28","author":"Wang","year":"2023","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:48:46Z","timestamp":1760035726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["curroncol32090523"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32090523","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]}}}